Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

454 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial.
Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P, Hochman JS, Filloon TG, Mojcik CF, Todaro TG, Armstrong PW; COMPLY Investigators. Mahaffey KW, et al. Among authors: hochman js. Circulation. 2003 Sep 9;108(10):1176-83. doi: 10.1161/01.CIR.0000087404.53661.F8. Epub 2003 Aug 18. Circulation. 2003. PMID: 12925455 Clinical Trial.
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, Armstrong PW; COMMA Investigators. Granger CB, et al. Among authors: hochman js. Circulation. 2003 Sep 9;108(10):1184-90. doi: 10.1161/01.CIR.0000087447.12918.85. Epub 2003 Aug 18. Circulation. 2003. PMID: 12925454 Clinical Trial.
Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial).
Patel MR, Mahaffey KW, Armstrong PW, Weaver WD, Tasissa G, Hochman JS, Todaro TG, Malloy KJ, Rollins S, Theroux P, Ruzyllo W, Nicolau JC, Granger CB; CARDINAL Investigators. Patel MR, et al. Among authors: hochman js. Am J Cardiol. 2005 Mar 1;95(5):614-8. doi: 10.1016/j.amjcard.2004.11.008. Am J Cardiol. 2005. PMID: 15721102 Clinical Trial.
Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial.
Lopes RD, Elliott LE, White HD, Hochman JS, Van de Werf F, Ardissino D, Nielsen TT, Weaver WD, Widimsky P, Armstrong PW, Granger CB. Lopes RD, et al. Among authors: hochman js. Eur Heart J. 2009 Aug;30(16):2019-28. doi: 10.1093/eurheartj/ehp213. Epub 2009 Jun 6. Eur Heart J. 2009. PMID: 19502623 Free PMC article. Clinical Trial.
Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study.
Bagai A, Armstrong PW, Stebbins A, Mahaffey KW, Hochman JS, Weaver WD, Patel MR, Granger CB, Lopes RD. Bagai A, et al. Among authors: hochman js. Am Heart J. 2013 Nov;166(5):913-9. doi: 10.1016/j.ahj.2013.08.006. Epub 2013 Sep 24. Am Heart J. 2013. PMID: 24176448 Clinical Trial.
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
Dyke CK, Becker RC, Kleiman NS, Hochman JS, Bovill EG, Lincoff AM, Gerstenblith G, Dzavik V, Gardner LH, Hasselblad V, Zillman LA, Shimoto Y, Robertson TL, Kunitada S, Armstrong PW, Harrington RA. Dyke CK, et al. Among authors: hochman js. Circulation. 2002 May 21;105(20):2385-91. doi: 10.1161/01.cir.0000016351.12759.52. Circulation. 2002. PMID: 12021225 Clinical Trial.
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial.
Théroux P, Armstrong PW, Mahaffey KW, Hochman JS, Malloy KJ, Rollins S, Nicolau JC, Lavoie J, Luong TM, Burchenal J, Granger CB. Théroux P, et al. Among authors: hochman js. Eur Heart J. 2005 Oct;26(19):1964-70. doi: 10.1093/eurheartj/ehi292. Epub 2005 May 4. Eur Heart J. 2005. PMID: 15872036 Clinical Trial.
454 results